{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:15:15Z","timestamp":1783030515654,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Private Donations"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Accurate measurement of phenylalanine (Phe) is a requirement for the diagnosis and management of individuals with Phenylketonuria (PKU). The current methods for quantifying Phe, plasma amino acids, and dried blood spots (DBS) have several analytical limitations and are not suitable for self-monitoring. This study evaluated the validity of a point-of-care testing (POCT) device, the Egoo Phe Test, in a sample of females with PKU who participated in a five-day camp intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Blood samples were collected from 20 participants (median age: 18\u00a0years; IQR: 16, 28.3) on the first (day 1) and\/or final (day 5) day of camp for Phe quantification by plasma amino acids, DBS, and the Egoo Phe Test. Phe concentrations determined by these three methods were compared to assess agreement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>On both days of camp, strong positive agreement based on Lin\u2019s concordance correlation coefficient (<jats:italic>p<\/jats:italic>\n              <jats:sub>\n                <jats:italic>c<\/jats:italic>\n              <\/jats:sub>\n              <jats:italic>)<\/jats:italic> was found between Egoo and DBS (day 1: <jats:italic>p<\/jats:italic>\n              <jats:sub>\n                <jats:italic>c<\/jats:italic>\n              <\/jats:sub>\u2009=\u20090.91 [95% CI<jats:italic>:<\/jats:italic> 0.78, 0.96]; day 5: <jats:italic>p<\/jats:italic>\n              <jats:sub>\n                <jats:italic>c<\/jats:italic>\n              <\/jats:sub>\u2009=\u20090.91 [95% CI: 0.79, 0.96]) and moderate positive agreement was identified between Egoo and plasma amino acids (day 1 <jats:italic>p<\/jats:italic>\n              <jats:sub>\n                <jats:italic>c<\/jats:italic>\n              <\/jats:sub>\u2009=\u20090.80 [95% CI: 0.63, 0.89]; day 5 <jats:italic>p<\/jats:italic>\n              <jats:sub>\n                <jats:italic>c<\/jats:italic>\n              <\/jats:sub>\u2009=\u20090.83 [95% CI: 0.68, 0.91]). Phe concentrations measured by the Egoo were lower than Phe concentrations determined by plasma amino acids (day 1 average difference: -31.2% [95% CI: \u2212\u200940.2, \u2212\u200925.8]; day 5 average difference: -12.4% [95% CI: -30.4, \u2212\u20094.2]) and higher than DBS (day 1 average difference: 16.2% [95% CI: 4.6, 25.3]; day 5 average difference: 12.2% [95% CI: \u2212\u20091.4, 20.5]). When assessing pairwise differences between the methods for each sample,\u2009&gt;\u200966.7% of the Egoo Phe results were within\u2009\u00b1\u200920% difference of the DBS values on day 5 of camp. However, this criterion was not met when comparing Egoo with DBS on day 1 of camp or with plasma amino acids on either day of camp.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The Egoo Phe Test demonstrated potential as a substitute for DBS, but additional research in larger and more diverse clinical cohorts is required. Future research should focus on improving accuracy and defining analytical targets that consider the clinical impact of Phe test performance on management of patients with PKU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number:<\/jats:title>\n            <jats:p>not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03989-6","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:57:21Z","timestamp":1760086641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Performance of the Egoo test for phenylalanine measurement in females with phenylketonuria"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-2247","authenticated-orcid":false,"given":"Meriah S.","family":"Schoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serei Vatana","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani H.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3989_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"FJ van Spronsen","year":"2021","unstructured":"van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021;7:1\u201319.","journal-title":"Nat Rev Dis Primers"},{"key":"3989_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107583","volume":"1391","author":"V Rovelli","year":"2023","unstructured":"Rovelli V, Longo N. Phenylketonuria and the brain. Mol Genet Metab. 2023;1391: 107583.","journal-title":"Mol Genet Metab"},{"key":"3989_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16:188.","journal-title":"Genet Med"},{"key":"3989_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ymgme.2016.04.008","volume":"118","author":"RH Singh","year":"2016","unstructured":"Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, Hook DG, Jeffers L, McCune H, Moseley KD, Ogata B. Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach. Mol Genet Metab. 2016;118:72\u201383.","journal-title":"Mol Genet Metab"},{"key":"3989_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13023-023-02751-0","volume":"18","author":"A Cunningham","year":"2023","unstructured":"Cunningham A, Rohr F, Splett P, Mofidi S, Bausell H, Stembridge A, Kenneson A, Singh RH. Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations. Orphanet J Rare Dis. 2023;18:155.","journal-title":"Orphanet J Rare Dis"},{"key":"3989_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/GIM.0b013e318159a355","volume":"9","author":"CO Gregory","year":"2007","unstructured":"Gregory CO, Yu C, Singh RH. Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med. 2007;9:761\u20135.","journal-title":"Genet Med"},{"key":"3989_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","volume":"130","author":"Y Enderle","year":"2016","unstructured":"Enderle Y, Foerster K, Burhenne J. Clinical feasibility of dried blood spots: analytics, validation, and applications. J Pharm Biomed Anal. 2016;130:231\u201343.","journal-title":"J Pharm Biomed Anal"},{"key":"3989_CR8","first-page":"70","volume":"58","author":"KLM Coene","year":"2021","unstructured":"Coene KLM, Timmer C, Goorden SMI, Ten Hoedt AE, Kluijtmans LAJ, Janssen MCH, Rennings AJM, Prinsen H, Wamelink MMC, Ruijter GJG, K\u00f6rver-Keularts I, Heiner-Fokkema MR, van Spronsen FJ, Hollak CE, Vaz FM, Bosch AM, Huigen M. Monitoring phenylalanine concentrations in the follow-up of phenylketonuria patients: An inventory of pre-analytical and analytical variation. JIMD Rep. 2021;58:70\u20139.","journal-title":"JIMD Rep"},{"key":"3989_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6020026","volume":"6","author":"SJ Moat","year":"2020","unstructured":"Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen. 2020;6: 26.","journal-title":"Int J Neonatal Screen"},{"key":"3989_CR10","first-page":"21","volume":"6","author":"BM Stroup","year":"2016","unstructured":"Stroup BM, Held PK, Williams P, Clayton MK, Murali SG, Rice GM, Ney DM. Clinical relevance of the discrepancy in phenylalanine concentrations analyzed using tandem mass spectrometry compared with ion-exchange chromatography in phenylketonuria. Mol Genet Metab Rep. 2016;6:21\u20136.","journal-title":"Mol Genet Metab Rep"},{"key":"3989_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-020-1343-7","volume":"15","author":"K van Vliet","year":"2020","unstructured":"van Vliet K, van Ginkel WG, van Dam E, de Blaauw P, Koehorst M, Kingma HA, van Spronsen FJ, Heiner-Fokkema MR. Dried blood spot versus venous blood sampling for phenylalanine and tyrosine. Orphanet J Rare Dis. 2020;15:82.","journal-title":"Orphanet J Rare Dis"},{"key":"3989_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108361","volume":"142","author":"AM Kuypers","year":"2024","unstructured":"Kuypers AM, Vliet KE, MacDonald A, Ahring K, Abeln D, Ford S, Hildebrandt-Karlsen S, van Spronsen FJ, Heiner-Fokkema MR. Satisfaction with home blood sampling methods and expectations for future point-of-care testing in phenylketonuria: Perspectives from patients and professionals. Mol Genet Metab. 2024;142: 108361.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"3989_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/s20092496","volume":"20","author":"A Dinu","year":"2020","unstructured":"Dinu A, Apetrei C. A review on electrochemical sensors and biosensors used in phenylalanine electroanalysis. Sensors. 2020;20(9): 2496.","journal-title":"Sensors"},{"key":"3989_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0002-8223(00)00232-7","volume":"100","author":"RH Singh","year":"2000","unstructured":"Singh RH, Kable JA, Guerrero NV, Sullivan KM, Elsas LJ II. Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls. J Am Diet Assoc. 2000;100:797\u2013803.","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"3989_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"8","author":"J Bland","year":"1986","unstructured":"Bland J. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8(1):307\u201310.","journal-title":"Lancet"},{"issue":"1","key":"3989_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/uog.122","volume":"22","author":"JM Bland","year":"2003","unstructured":"Bland JM, Altman DG. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol. 2003;22(1):85\u201393.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"3989_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"A Lin","year":"1989","unstructured":"Lin A. Concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255\u201368.","journal-title":"Biometrics"},{"key":"3989_CR18","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline, Bioanalytical method validation and study sample analysis M10. 2022. Geneva, Switzerland."},{"issue":"1","key":"3989_CR19","first-page":"171","volume":"15","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, Van Wegberg A, Ahring K, Beblo S, B\u00e9langer-Quintana A, Burlina A, Campistol J, Co\u015fkun T, Feillet F, Gi\u017cewska M, et al. PKU dietary handbook to accompany PKU guidelines Orphanet. J Rare Dis. 2020;15(1):171.","journal-title":"J Rare Dis"},{"issue":"3","key":"3989_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","volume":"120","author":"E Jurecki","year":"2017","unstructured":"Jurecki E, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A, Viau K, Sheinin M, Cohen-Pfeffer J. Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol Genet Metab. 2017;120(3):190\u20137.","journal-title":"Mol Genet Metab"},{"key":"3989_CR21","first-page":"8","volume":"6","author":"CS Brown","year":"2016","unstructured":"Brown CS, Lichter-Konecki U. Phenylketonuria (PKU): a problem solved? Mol Genet Metab Rep. 2016;6:8\u201312.","journal-title":"Mol Genet Metab Rep"},{"issue":"9326","key":"3989_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","volume":"360","author":"J Walter","year":"2002","unstructured":"Walter J, White F, Hall S, MacDonald A, Rylance G, Boneh A, Francis D, Shortland G, Schmidt M, Vail A. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002;360(9326):55\u20137.","journal-title":"Lancet"},{"key":"3989_CR23","first-page":"1","volume":"31","author":"G Luca Russo","year":"2024","unstructured":"Luca Russo G, Puleo S, Cavella S, Scala I, Fidaleo M, Di Monaco R. Advances in food science for Phenylketonuria (PKU) management: a comprehensive review. Crit Rev Food Sci Nutr. 2024;31:1\u201315.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"3989_CR24","volume":"23","author":"CO Harding","year":"2024","unstructured":"Harding CO, Longo N, Northrup H, Sacharow S, Singh R, Thomas JA, Vockley J, Zori RT, Whitehall KB, Lilienstein J, Lindstrom K, Levy DG, Jones S, Burton BK. Pegvaliase for the treatment of phenylketonuira: final results of a long-term phase 3 clinical trial program. Mol Genet Metab Rep. 2024;23: 101084.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"3989_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ymgme.2015.02.003","volume":"114","author":"N Longo","year":"2015","unstructured":"Longo N, Arnold GL, Pridjian G, Enns GM, Ficicioglu C, Parker S, Cohen-Pfeffer JL. Long-term safety and efficacy of sapropterin: the PKUDOS registry experience. Mol Genet Metab. 2015;114(4):557\u201363.","journal-title":"Mol Genet Metab"},{"key":"3989_CR26","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1007\/PL00014224","volume":"155","author":"U Wendel","year":"1996","unstructured":"Wendel U, Langenbeck U. Towards self-monitoring and self-treatment in phenylketonuria\u2014a way to better diet compliance. Eur J Pediatr. 1996;155:S105\u20137.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"3989_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10545-010-9073-y","volume":"33","author":"A MacDonald","year":"2010","unstructured":"MacDonald A, Gokmen-Ozel H, van Rijn M, Burgard P. The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010;33(6):665\u201370.","journal-title":"J Inherit Metab Dis"},{"key":"3989_CR28","unstructured":"Waitzman N, Bilginsoy C, Leonard CO, Ernst SL, Prince A. The effect of phenylalanine test frequency on management of phenylketonuria (PKU). University of Utah. 2004."},{"issue":"3","key":"3989_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10545-011-9335-3","volume":"34","author":"FJ White","year":"2011","unstructured":"White FJ, Jones SA. The use of continuous glucose monitoring in the practical management of glycogen storage disorders. J Inherit Metab Dis. 2011;34(3):631\u201342.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3989_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s10545-018-0200-5","volume":"41","author":"M Herbert","year":"2018","unstructured":"Herbert M, Pendyal S, Rairikar M, Halaby C, Benjamin RW, Kishnani PS. Role of continuous glucose monitoring in the management of glycogen storage disorders. J Inherit Metab Dis. 2018;41(6):917\u201327.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3989_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ejcn.2013.186","volume":"68","author":"\u00c7S Kasapkara","year":"2014","unstructured":"Kasapkara \u00c7S, Cinasal Demir G, Hasano\u011flu A, T\u00fcmer L. Continuous glucose monitoring in children with glycogen storage disease type I. Eur J Clin Nutr. 2014;68(1):101\u20135.","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"3989_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1037\/neu0000336","volume":"31","author":"C Romani","year":"2017","unstructured":"Romani C, Palermo L, MacDonald A, Limback E, Hall SK, Geberhiwot T. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages. Neuropsychology. 2017;31(3):242\u201354.","journal-title":"Neuropsychology"},{"issue":"4","key":"3989_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ymgme.2014.01.012","volume":"111","author":"A Hood","year":"2014","unstructured":"Hood A, Grange DK, Christ SE, Steiner R, White DA. Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria. Mol Genet Metab. 2014;111(4):445\u201351.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3989_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jimd.12163","volume":"43","author":"SJ Moat","year":"2020","unstructured":"Moat SJ, Schulenburg-Brand D, Lemonde H, Bonham JR, Weykamp CW, Mei JV, Shortland GS, Carling RS. Performance of laboratory tests used to measure blood phenylalanine for the monitoring of patients with phenylketonuria. J Inherit Metab Dis. 2020;43(2):179\u201388.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3989_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/CCLM.2010.008","volume":"48","author":"Z Corte","year":"2010","unstructured":"Corte Z, Venta R. Biological variation of free plasma amino acids in healthy individuals. Clin Chem Lab Med. 2010;48(1):99\u2013104.","journal-title":"Clin Chem Lab Med"},{"key":"3989_CR36","volume":"240","author":"C Turgeon","year":"2024","unstructured":"Turgeon C, Casas K, Flanagan R, White A, Peck D, Pino GB, Jones AS, Gavrilov D, Oglesbee D, Schultz MJ, et al. Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase. Mol Genet Metab Rep. 2024;240: 101110.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03989-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03989-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03989-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:57:24Z","timestamp":1760086644000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03989-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3989"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03989-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Internal Review Board at Emory University (00002447) and was carried out in accordance with the provisions of the World Medical Association Declaration of Helsinki. Informed consent was obtained for all individuals prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"RHS has served on advisory boards for Danone and Synlogic Therapeutics. RHS has also served as PI for research studies funded by BioMarin. MSS received honoraria from Ajinomoto Cambrooke and Relief Therapeutics for presentations at educational events. SN has no competing interests to disclose. The authors confirm independence from the aforementioned entities; the content of the article has not been influenced by the entities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"510"}}